Axcella Health (AXLA) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Axcella Reports First Quarter Financial Results and Provides Business Update
May 6, 2021 7:28 AM EDTAXA1665 IND application cleared by FDA for the reduction in risk of recurrent OHE AXA1125 IND application cleared by FDA for the treatment of NASH Initiation of AXA1665 Phase 2 and AXA1125 Phase 2b clinical trials expected shortly Company to host conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial... More
